Almstead Neil Gregory, an insider at PTC Therapeutics Inc (PTCT), sold 100,625 shares on November 23, 2025, at a price of $80.14 per share, totaling $8.06 million. Following this transaction, Gregory retains 100,625 shares of the company.
PTC Therapeutics, a biopharmaceutical firm based in Warren, New Jersey, focuses on developing medicines for rare disorders. With a market cap of $6.9 billion, the company reported a P/E ratio of 9.21 and an EPS of 8.53. PTC’s portfolio includes treatments for conditions such as Duchenne muscular dystrophy and spinal muscular atrophy.
Insider sales can arise from various personal or financial reasons, including diversification or tax planning. However, such transactions should not be the sole basis for investment decisions. Investors are advised to consider broader patterns of insider activity across multiple executives.
Upcoming earnings reports for PTC Therapeutics are scheduled for May 4, 2026, and August 5, 2026, with estimated EPS of $-0.64 and $-0.54, respectively.